Abstract
6H-Indolo[2,3-b]quinoxaline, a planar fused heterocyclic compound exhibits a wide variety of pharmacological activities. The mechanism of pharmacological action exerted by these compounds is predominantly DNA intercalation. The thermal stability of the intercalated complex (DNA and 6H-indolo[2,3-b]quinoxaline derivatives) is an important parameter for the elucidation of anticancer, antiviral and other activities. This thermal stability of the 6H-indolo[2,3- b]quinoxaline–DNA complex depends on the type of substituents and side chains attached to the 6H-indolo[2,3- b]quinoxaline nucleus and also the orientation of the side chain towards the GC rich minor groove of the DNA. Highly active 6H-indolo[2,3-b]quinoxaline derivatives such as NCA0424, B-220 and 9-OH-B-220 have shown good binding affinity to DNA as evident from high thermal stability of compound-DNA complex. Interestingly, these compounds possessed poor inhibitory activity on topoisomerase II enzyme but have significant MDR modulating activity. This review establishes ‘6H-indolo[2,3-b]quinoxaline’ as a valuable template for design and development of novel molecules with different biological activities.
Keywords: 6H-indolo[2, 3-b]quinoxalines, anticancer, antiviral, P-glycoprotein, DNA intercalation.
Mini-Reviews in Medicinal Chemistry
Title:6H-Indolo[2,3-b]Quinoxalines: DNA and Protein Interacting Scaffold for Pharmacological Activities
Volume: 13 Issue: 10
Author(s): N.S. Hari Narayana Moorthy, E. Manivannan, C. Karthikeyan and Piyush Trivedi
Affiliation:
Keywords: 6H-indolo[2, 3-b]quinoxalines, anticancer, antiviral, P-glycoprotein, DNA intercalation.
Abstract: 6H-Indolo[2,3-b]quinoxaline, a planar fused heterocyclic compound exhibits a wide variety of pharmacological activities. The mechanism of pharmacological action exerted by these compounds is predominantly DNA intercalation. The thermal stability of the intercalated complex (DNA and 6H-indolo[2,3-b]quinoxaline derivatives) is an important parameter for the elucidation of anticancer, antiviral and other activities. This thermal stability of the 6H-indolo[2,3- b]quinoxaline–DNA complex depends on the type of substituents and side chains attached to the 6H-indolo[2,3- b]quinoxaline nucleus and also the orientation of the side chain towards the GC rich minor groove of the DNA. Highly active 6H-indolo[2,3-b]quinoxaline derivatives such as NCA0424, B-220 and 9-OH-B-220 have shown good binding affinity to DNA as evident from high thermal stability of compound-DNA complex. Interestingly, these compounds possessed poor inhibitory activity on topoisomerase II enzyme but have significant MDR modulating activity. This review establishes ‘6H-indolo[2,3-b]quinoxaline’ as a valuable template for design and development of novel molecules with different biological activities.
Export Options
About this article
Cite this article as:
Moorthy Narayana N.S. Hari, Manivannan E., Karthikeyan C. and Trivedi Piyush, 6H-Indolo[2,3-b]Quinoxalines: DNA and Protein Interacting Scaffold for Pharmacological Activities, Mini-Reviews in Medicinal Chemistry 2013; 13 (10) . https://dx.doi.org/10.2174/13895575113139990005
DOI https://dx.doi.org/10.2174/13895575113139990005 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating Traumatic Stress in Children and Adolescents
Adolescent Psychiatry Effect of Barley Grain on Memory and Brain’s Oxidative Stress Factors in Male Rats
The Natural Products Journal Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities
Current Neuropharmacology Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Patent Review on Laser Interference Lithography Technique for Producing Periodic Nanostructure
Recent Patents on Nanotechnology Gender Difference Response of Male and Female Immunodeficiency Rats Treated with Tissue-specific Biomolecules
Current Pharmaceutical Biotechnology Withanolides from Withania somnifera Dunal: Development of Cellular Technology and their Production
Recent Patents on Biotechnology High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews The Role of Neuroimaging in Our Understanding of the Suicidal Brain
CNS & Neurological Disorders - Drug Targets The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology Editorial [Hot Topic: Perspectives in Integrin Blocking (Executive Editor: C. Marcinkiewicz)]
Current Pharmaceutical Design Inflammatory Aspects of Depression
Inflammation & Allergy - Drug Targets (Discontinued) PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis
Current Medicinal Chemistry Determination of Cr(VI) by Dispersive Liquid-Liquid Microextraction and Dried-Droplet Laser Ablation ICP-MS
Current Analytical Chemistry Physiological and Morphological Principles Underpinning Recruitment of the Cerebellar Reserve
CNS & Neurological Disorders - Drug Targets Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design The Endocannabinoid/Endovanilloid System and Depression
Current Neuropharmacology